MENU
+Compare
CMPX
Stock ticker: NASDAQ
AS OF
May 23, 04:59 PM (EDT)
Price
$2.08
Change
+$0.03 (+1.46%)
Capitalization
290.39M

CMPX Compass Therapeutics Forecast, Technical & Fundamental Analysis

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies... Show more

CMPX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CMPX with price predictions
May 22, 2025

Aroon Indicator for CMPX shows an upward move is likely

CMPX's Aroon Indicator triggered a bullish signal on May 22, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 116 similar instances where the Aroon Indicator showed a similar pattern. In of the 116 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 12, 2025. You may want to consider a long position or call options on CMPX as a result. In of 70 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

CMPX moved above its 50-day moving average on May 15, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CMPX crossed bullishly above the 50-day moving average on May 21, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CMPX advanced for three days, in of 182 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMPX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CMPX broke above its upper Bollinger Band on April 22, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CMPX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.633) is normal, around the industry mean (16.302). P/E Ratio (0.000) is within average values for comparable stocks, (59.789). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.190). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (344.828) is also within normal values, averaging (277.726).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
CMPX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

CMPX is expected to report earnings to rise 2.75% to -12 cents per share on July 30

Compass Therapeutics CMPX Stock Earnings Reports
Q2'25
Est.
$-0.12
Q1'25
Missed
by $0.01
Q4'24
Missed
by $0.01
Q3'24
Beat
by $0.03
Q2'24
Est.
$-0.10
The last earnings report on May 08 showed earnings per share of -11 cents, missing the estimate of -10 cents. With 253.39K shares outstanding, the current market capitalization sits at 290.39M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
80 Guest Street
Phone
+1 617 500-8099
Employees
32
Web
https://www.compasstherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PFSZX24.37N/A
N/A
PGIM Jennison Financial Services Z
SVSPX256.08N/A
N/A
State Street S&P 500 Index N
BPSCX23.30N/A
N/A
Boston Partners Small Cap Value II Inv
GEMOX12.45N/A
N/A
Goldman Sachs Emerging Mkt Eq ex. ChnInv
HFQRX6.77-0.01
-0.15%
Janus Henderson Global Equity Income N

CMPX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CMPX has been loosely correlated with VCYT. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CMPX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CMPX
1D Price
Change %
CMPX100%
N/A
VCYT - CMPX
37%
Loosely correlated
N/A
FHTX - CMPX
35%
Loosely correlated
+1.97%
SANA - CMPX
35%
Loosely correlated
N/A
CPRX - CMPX
35%
Loosely correlated
-0.86%
VIR - CMPX
35%
Loosely correlated
N/A
More